ENTRAYNIA

Serial Number 99457144
680

Registration Progress

Application Filed
Oct 22, 2025
Under Examination
Approved for Publication
Published for Opposition
Registered

Trademark Image

ENTRAYNIA

Basic Information

Serial Number
99457144
Filing Date
October 22, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
680
Status Date
Dec 15, 2025
Application
Pending
Classes
005

Rights Holder

Vanda Pharmaceuticals Inc.

03
Address
2200 Pennsylvania Ave. NW
Suite 300E
Washington, DC 20037

Ownership History

Vanda Pharmaceuticals Inc.

Original Applicant
03
Washington, DC

Legal Representation

Attorney
Jayme M. Torelli

Application History

5 events
Date Code Type Description Documents
Dec 15, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 10, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 22, 2025 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Oct 22, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 22, 2025 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment of Non-24-Hour Sleep-Wake Disorder; Pharmaceutical preparations for the treatment of circadian rhythm diseases and disorders; Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations for the treatment of Smith-Magenis Syndrome; Pharmaceutical preparations for the treatment of nighttime sleep disturbances in patients with Smith-Magenis Syndrome (SMS); Pharmaceutical preparations for the treatment of Delayed Sleep Phase Disorder; Pharmaceutical preparations for the treatment of bipolar disorder; Pharmaceutical preparations for the treatment of schizophrenia; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of hematologic malignancies; Pharmaceutical preparations for the treatment of fatigue; Pharmaceutical preparations for the treatment of narcolepsy; Pharmaceutical preparations for the treatment of levodopa-induced dyskinesias in Parkinson's Disease; Pharmaceutical preparations for the treatment of viral pneumonia; Pharmaceutical preparations for the treatment of social anxiety disorder and social anxiety disorder performance-only subtype; Pharmaceutical preparations for the treatment of respiratory distress, acute respiratory distress syndrome, and inflammatory lung injury; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of multiple myeloma; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for the central nervous system; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations, namely, antivirals; Pharmaceutical preparations for the reduction of cravings for alcohol, food, nicotine, opioids, or opiates; Pharmaceutical preparations for facilitating emergence from general anesthesia; Pharmaceutical preparations for improving cognition; Pharmaceutical preparations for the treatment of gastric motility and gastric emptying disorders

Classification

International Classes
005